JP Morgan Cazenove reiterated Shire PLC (LON:SHP) to Overweight in a report released today.
- Updated: October 16, 2016
JP Morgan Cazenove has reiterated Shire PLC (LON:SHP) to Overweight in a report released on 10/17/2016.
Previously on 10/07/2016, Credit Suisse reported on Shire PLC (LON:SHP) held steady the target price at 5,200.00GBX. At the time, this indicated a possible upside of 0.02%.
Yesterday Shire PLC (LON:SHP) traded -0.43% lower at 5,123.00GBX. The company’s 50-day moving average is 5,005.03GBX and its 200-day moving average is 4,600.81GBX. The last closing price is up 11.39% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 152,670 shares of the stock were exchanged, down from an average trading volume of 1,859,780
See Chart Below
Shire PLC has a 52 week low of 2,707.19GBX and a 52 week high of 5,377.00GBX with a P/E ratio of 31.95 The company’s market cap is currently 0 GBX.
In addition to JP Morgan Cazenove reporting its target price, a total of 18 brokers have issued a report on the stock. The consensus target price is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.